Skip directly to our latest press releases.

AuRx, Inc. is a biotechnology company specializing in the treatment of long lasting and recurrent viral disease. The initial program has been the development of AuRx therapy for genital herpes (HSV-2). Current treatments for genital herpes seek to reduce the duration of each recurrent episode, whereas the AuRx therapy seeks to prevent the recurrence of lesions. AuRx has completed a Phase I/II trial in Mexico City and the initial results show that it was well tolerated (adverse events were similar to those of a sugar pill, mainly headache and malaise) and significantly reduced the number of herpetic episodes from the previous year. You may read more about this trial under Press Releases and the abstract is available below.

Four papers describing the AuRx therapeutic vaccine and its effectiveness in animals and humans have been published.

Casanova G, Cancela R, Alonzo L, Benuto R, del Carmen Magana M, Hurley DP, Fishbein E, Lara C, Gonzalez T, Ponce R, Burnett JW, Calton GJ. A double-blind study of the efficacy and safety of the ICP10DPK vaccine against recurrent genital HSV-2 infections. Cutis. 2002;70(4):235-239

continue